EZH2 and cancer: In 2020, we combined chemical propionylation-based Kme1 enrichment and pan-antibody-based Kme2 and Kme3 enrichment to study lysine methylome features in wild-type and mutant Enhancer of zeste homolog 2 (EZH2) cancer cells [93].